NICE has issued further draft guidance for consultation that recommends obinutuzumab, marketed by Roche as Gazyvaro, for some people with untreated chronic lymphocytic leukaemia (CLL).
CLL is the most common form of leukaemia in England, with around 2,700 people being diagnosed with the condition each year.
Newsletter of the CLL Support Association
Inside this Issue
Page 1 Patient Meeting Nov 06
New Trials Articles
Page 2 Was it a Nice Meeting?
Page 3 Familial Reseach Project
Bristol Cancer Help Centre
Page 4 New Articles Available
Page 5 Research Project
All articles contained in this newsletter have been written by Dr Howard Pearce
Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi. Nam eget dui. Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus.
Clinical care blog. Test for demo 30/01/15 clinical care blog for use by CLLSA clinical advisers, and external clinical care providers to update with resources, news and guidance
Research Info.............. Test for demo 30/01/15 Research blog content for CLLSA approved research volunteer panel, representatives from CLL research centres, to update on latest developments and perspectives
International NY test for demo 30/01/15 Blog for use by CLLSA approved internatuinal clinical care advisers & PAG CLL advocates to sign post to international perspectives , guidelines and resources and update with developments and news
Partner Organisations Test for demo 30/01/15 fro use by partner oraganisations, LLR, LC, LA, MAC, PP, PPEU, CLLPAG etc to update with resources to support CLL patients and their families